Table 1.24 Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity Both Sexes

| All Races  |   |  | White  |   |  | Black  |   |  |
|--|---|--|--|---|--|--|---|--|
|  | Rate <sup>b</sup><br>2008-2012  | APC°<br>2003-2012  |  | Rate <sup>b</sup><br>2008-2012  | APC°<br>2003-2012  |  | Rate <sup>b</sup><br>2008-2012  | APC <sup>c</sup><br>2003-2012                                  |
| All Sites  | 454.8   | -0.7*  | All Sites  | 463.3   | -0.7*  | All Sites  | 478.0   | -1.1*  |
| Breast   | 67.2  | 0.0  | Breast   | 68.1  | -0.1   | Prostate <sup>f</sup>  | 91.2  | -2.4*  |
| Prostate <sup>f</sup>  | 62.7  | -2.4*  | Lung and Bronchus  | 60.2  | -1.8*  | Breast   | 70.8  | 0.5  |
| Lung and Bronchus  | 58.7  | -1.9*  | Prostate <sup>f</sup>  | 60.0  | -2.7*  | Lung and Bronchus  | 67.0  | -2.1*  |
| Colon and Rectum   | 42.4  | -2.8*  | Colon and Rectum   | 41.5  | -2.9*  | Colon and Rectum   | 52.3  | -2.8*  |
| Melanoma of the Skin   | 21.6  | 1.2*   | Melanoma of the Skin   | 25.6  | 1.2*   | Kidney and Renal Pelvis  | 18.1  | 2.3*   |
| Urinary Bladder  | 20.3  | -0.9*  | Urinary Bladder  | 22.2  | -0.9*  | Pancreas   | 15.7  | -0.3   |
| Non-Hodgkin Lymphoma   | 19.7  | -0.3   | Non-Hodgkin Lymphoma   | 20.6  | -0.3   | Non-Hodgkin Lymphoma   | 14.6  | -0.4   |
| Kidney and Renal Pelvis  | 15.6  | 1.5*   | Kidney and Renal Pelvis  | 16.1  | 1.5*   | Corpus and Uterus, NOSf  | 13.6  | 2.6*   |
| Thyroid  | 13.5  | 5.4*   | Thyroid  | 14.3  | 5.4*   | Myeloma  | 12.8  | 0.7*   |
| Corpus and Uterus, NOS <sup>f</sup>  | 13.4  | 1.3*   | Leukemia   | 14.0  | 0.2  | Urinary Bladder  | 12.6  | -0.6   |
| Leukemia   | 13.3  | 0.2  | Corpus and Uterus, NOS <sup>f</sup>  | 13.6  | 1.1*   | Stomach  | 10.9  | -2.2*  |
| Pancreas   | 12.4  | 0.7*   | Pancreas   | 12.3  | 0.9*   | Leukemia   | 10.6  | -0.3   |
| Oral Cavity and Pharynx  | 11.0  | 0.5*   | Oral Cavity and Pharynx  | 11.5  | 0.9*   | Liver & IBD <sup>g</sup>   | 9.8   | 3.2*   |
| Liver & IBD <sup>g</sup>   | 8.2   | 3.1*   | Liver & IBD <sup>g</sup>   | 7.2   | 3.8*   | Oral Cavity and Pharynx  | 9.3   | -2.3*  |
| Stomach  | 7.4   | -1.1*  | Brain and ONS <sup>9</sup>   | 7.1   | -0.5*  | Thyroid  | 8.0   | 4.9*   |
| Asian/Pacific Islander   |   |  | American Indian/Alaska Native <sup>d</sup>   |   |  | Hispanic <sup>e</sup>  |   |  |
|  | Rate <sup>b</sup>   | APCc   |  | Rate <sup>b</sup>   | APC <sup>c</sup>   |  | Rateb   | APC <sup>c</sup>   |
|  | 2000 2012   | 2002 2012  |  | 2008-2012   | 2002 2012  |  | 2008-2012   | 2003-2012  |
|  |   | 2003-2012  |  |   |  |  |   |  |
| All Sites  | 306.8   | -0.9*  | All Sites  | 319.7   | -1.3*  | All Sites  | 349.9   | -1.0*  |
| Breast   | 306.8<br>53.1   | -0.9*<br>1.0*  | Breast   | 319.7<br>44.1   | -1.3*<br>-0.1  | All Sites<br>Prostate <sup>f</sup>   | 349.9<br>50.7   | -3.6*  |
|  | 306.8   | -0.9*<br>1.0*<br>-1.5*   |  | 319.7   | -1.3*  |  | 349.9   | -3.6*<br>0.1   |
| Breast   | 306.8<br>53.1   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*  | Breast<br>Colon and Rectum<br>Lung and Bronchus  | 319.7<br>44.1   | -1.3*<br>-0.1<br>-1.6*<br>-3.9*                                  | Prostate <sup>f</sup>  | 349.9<br>50.7   | -3.6*<br>0.1<br>-2.2*  |
| Breast<br>Lung and Bronchus  | 306.8<br>53.1<br>37.1<br>36.1<br>32.3   | -0.9*<br>1.0*<br>-1.5*   | Breast<br>Colon and Rectum   | 319.7<br>44.1<br>40.3   | -1.3*<br>-0.1<br>-1.6*   | Prostate <sup>f</sup><br>Breast  | 349.9<br>50.7<br>49.4   | -3.6*<br>0.1<br>-2.2*<br>-2.4*                                 |
| Breast<br>Lung and Bronchus<br>Colon and Rectum  | 306.8<br>53.1<br>37.1<br>36.1   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*  | Breast<br>Colon and Rectum<br>Lung and Bronchus  | 319.7<br>44.1<br>40.3<br>39.9<br>29.8   | -1.3*<br>-0.1<br>-1.6*<br>-3.9*                                  | Prostate <sup>f</sup> Breast Colon and Rectum  | 349.9<br>50.7<br>49.4<br>35.8   | -3.6*<br>0.1<br>-2.2*<br>-2.4*<br>0.0                          |
| Breast<br>Lung and Bronchus<br>Colon and Rectum<br>Prostate <sup>f</sup>   | 306.8<br>53.1<br>37.1<br>36.1<br>32.3   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*<br>-4.6*<br>-1.3*                      | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Prostate <sup>f</sup>   | 319.7<br>44.1<br>40.3<br>39.9<br>29.8   | -1.3*<br>-0.1<br>-1.6*<br>-3.9*<br>-4.7*<br>-0.3<br>1.7          | Prostate <sup>f</sup><br>Breast<br>Colon and Rectum<br>Lung and Bronchus   | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2*                                 |
| Breast<br>Lung and Bronchus<br>Colon and Rectum<br>Prostate <sup>f</sup><br>Liver & IBD <sup>g</sup>   | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*<br>-4.6*<br>-1.3*                      | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Prostate <sup>f</sup><br>Kidney and Renal Pelvis  | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8   | -1.3*<br>-0.1<br>-1.6*<br>-3.9*<br>-4.7*<br>-0.3                 | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma   | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7*                            |
| Breast<br>Lung and Bronchus<br>Colon and Rectum<br>Prostate <sup>f</sup><br>Liver & IBD <sup>g</sup><br>Non-Hodgkin Lymphoma   | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*<br>-4.6*<br>-1.3*                      | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup>   | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6   | -1.3*<br>-0.1<br>-1.6*<br>-3.9*<br>-4.7*<br>-0.3<br>1.7          | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis   | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2*                                 |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid  | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2   | -0.9*<br>1.0*<br>-1.5*<br>-2.2*<br>-4.6*<br>-1.3*<br>-0.1<br>5.2*      | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma  | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6                                     | -1.3*<br>-0.1<br>-1.6*<br>-3.9*<br>-4.7*<br>-0.3<br>1.7<br>0.2   | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>g</sup>  | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7*                            |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid Stomach  | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2   | -0.9* 1.0* -1.5* -2.2* -4.6* -1.3* -0.1 5.2* -3.6*                     | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>9</sup> Non-Hodgkin Lymphoma Corpus and Uterus, NOS <sup>f</sup>  | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6<br>10.5                             | -1.3* -0.1 -1.6* -3.9* -4.7* -0.3 1.7 0.2 1.8                    | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>9</sup> Thyroid  | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7* 5.3*                       |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid Stomach Corpus and Uterus, NOS <sup>f</sup>  | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2<br>11.2                                     | -0.9* 1.0* -1.5* -2.2* -4.6* -1.3* -0.1 5.2* -3.6* 2.6*                | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Corpus and Uterus, NOS <sup>f</sup> Pancreas   | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6<br>10.5<br>9.9<br>9.5               | -1.3* -0.1 -1.6* -3.9* -4.7* -0.3 1.7 0.2 1.8 -2.1               | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>9</sup> Thyroid Urinary Bladder  | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5<br>11.5   | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7* 5.3* -1.4*                 |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid Stomach Corpus and Uterus, NOS <sup>f</sup> Pancreas   | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2<br>11.2<br>10.9<br>9.9                      | -0.9* 1.0* -1.5* -2.2* -4.6* -1.3* -0.1 5.2* -3.6* 2.6* 1.0*           | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Corpus and Uterus, NOS <sup>f</sup> Pancreas Stomach   | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6<br>10.5<br>9.9<br>9.5               | -1.3* -0.1 -1.6* -3.9* -4.7* -0.3 1.7 0.2 1.8 -2.1 -2.0          | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Thyroid Urinary Bladder Pancreas   | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5<br>11.5<br>11.2                                 | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7* 5.3* -1.4* -0.1            |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid Stomach Corpus and Uterus, NOS <sup>f</sup> Pancreas Urinary Bladder                         | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2<br>11.2<br>10.9<br>9.9<br>9.0               | -0.9* 1.0* -1.5* -2.2* -4.6* -1.3* -0.1 5.2* -3.6* 2.6* 1.0* -1.6*     | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Corpus and Uterus, NOS <sup>f</sup> Pancreas Stomach Oral Cavity and Pharynx                 | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6<br>10.5<br>9.9<br>9.5<br>8.8        | -1.3* -0.1 -1.6* -3.9* -4.7* -0.3 1.7 0.2 1.8 -2.1 -2.0 2.5      | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Thyroid Urinary Bladder Pancreas Corpus and Uterus, NOS <sup>f</sup>         | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5<br>11.5<br>11.2<br>11.1                         | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7* 5.3* -1.4* -0.1 2.2*       |
| Breast Lung and Bronchus Colon and Rectum Prostate <sup>f</sup> Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Thyroid Stomach Corpus and Uterus, NOS <sup>f</sup> Pancreas Urinary Bladder Kidney and Renal Pelvis | 306.8<br>53.1<br>37.1<br>36.1<br>32.3<br>13.7<br>13.6<br>13.2<br>11.2<br>10.9<br>9.9<br>9.0<br>8.2<br>7.8 | -0.9* 1.0* -1.5* -2.2* -4.6* -1.3* -0.1 5.2* -3.6* 2.6* 1.0* -1.6* 1.3 | Breast Colon and Rectum Lung and Bronchus Prostate <sup>f</sup> Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Non-Hodgkin Lymphoma Corpus and Uterus, NOS <sup>f</sup> Pancreas Stomach Oral Cavity and Pharynx Urinary Bladder | 319.7<br>44.1<br>40.3<br>39.9<br>29.8<br>18.8<br>13.6<br>12.6<br>10.5<br>9.9<br>9.5<br>8.8<br>8.5 | -1.3* -0.1 -1.6* -3.9* -4.7* -0.3 1.7 0.2 1.8 -2.1 -2.0 2.5 -0.9 | Prostate <sup>f</sup> Breast Colon and Rectum Lung and Bronchus Non-Hodgkin Lymphoma Kidney and Renal Pelvis Liver & IBD <sup>g</sup> Thyroid Urinary Bladder Pancreas Corpus and Uterus, NOS <sup>f</sup> Stomach | 349.9<br>50.7<br>49.4<br>35.8<br>30.4<br>17.8<br>15.4<br>12.5<br>11.5<br>11.2<br>11.1<br>11.0<br>10.9<br>10.5 | -3.6* 0.1 -2.2* -2.4* 0.0 1.2* 2.7* 5.3* -1.4* -0.1 2.2* -2.1* |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

- Top 15 cancer sites selected based on 2008-2012 age-adjusted rates for the race/ethnic group.
- Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
- Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. f
- The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
- IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.25 Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites  $^{\rm a}$  by Race/Ethnicity Males

| All Races                  |           |                  | White                          |                            |           | Black                      |                   |                  |
|----------------------------|-----------|------------------|--------------------------------|----------------------------|-----------|----------------------------|-------------------|------------------|
|                            | Rateb     | APC <sup>c</sup> |                                | $\mathtt{Rate}^\mathtt{b}$ | APC°      |                            | Rate <sup>b</sup> | APC <sup>c</sup> |
|                            | 2008-2012 | 2003-2012        |                                | 2008-2012                  | 2003-2012 |                            | 2008-2012         | 2003-2012        |
| All Sites                  | 516.6     | -1.3*            | All Sites                      | 519.8                      | -1.3*     | All Sites                  | 590.1             | -2.1*            |
| Prostate                   | 137.9     | -2.9*            | Prostate                       | 130.4                      | -3.2*     | Prostate                   | 214.5             | -2.9*            |
| Lung and Bronchus          | 70.1      | -2.6*            | Lung and Bronchus              | 70.3                       | -2.5*     | Lung and Bronchus          | 90.9              | -2.9*            |
| Colon and Rectum           | 48.9      | -3.1*            | Colon and Rectum               | 47.8                       | -3.3*     | Colon and Rectum           | 61.2              | -3.0*            |
| Urinary Bladder            | 35.8      | -1.0*            | Urinary Bladder                | 39.0                       | -1.0*     | Kidney and Renal Pelvis    | 25.1              | 1.7*             |
| Melanoma of the Skin       | 28.2      | 1.5*             | Melanoma of the Skin           | 33.0                       | 1.4*      | Urinary Bladder            | 21.4              | -0.3             |
| Non-Hodgkin Lymphoma       | 23.9      | -0.2             | Non-Hodgkin Lymphoma           | 24.9                       | -0.2      | Non-Hodgkin Lymphoma       | 17.8              | -0.8             |
| Kidney and Renal Pelvis    | 21.3      | 1.5*             | Kidney and Renal Pelvis        | 21.9                       | 1.5*      | Pancreas                   | 17.2              | -0.3             |
| Leukemia                   | 17.0      | 0.0              | Leukemia                       | 17.9                       | 0.0       | Liver & IBD <sup>f</sup>   | 16.2              | 3.4*             |
| Oral Cavity and Pharynx    | 16.5      | 0.5*             | Oral Cavity and Pharynx        | 17.1                       | 0.9*      | Myeloma                    | 15.1              | 0.1              |
| Pancreas                   | 14.0      | 0.8*             | Pancreas                       | 14.0                       | 0.9*      | Oral Cavity and Pharynx    | 14.6              | -2.4*            |
| Liver & IBD <sup>f</sup>   | 12.7      | 3.2*             | Liver & IBD <sup>f</sup>       | 11.2                       | 3.8*      | Stomach                    | 14.6              | -3.5*            |
| Stomach                    | 10.1      | -1.4*            | Stomach                        | 9.2                        | -0.9*     | Leukemia                   | 13.5              | -0.6             |
| Myeloma                    | 7.9       | 1.3*             | Brain and ONS <sup>f</sup>     | 8.4                        | -0.4      | Larynx                     | 8.8               | -3.3*            |
| Brain and ONS <sup>f</sup> | 7.7       | -0.4             | Esophagus                      | 8.0                        | -0.3      | Esophagus                  | 7.6               | -5.0*            |
| Esophagus                  | 7.6       | -1.0*            | Myeloma                        | 7.5                        | 1.4*      | Brain and ONS <sup>f</sup> | 4.9               | 0.2              |
| Asian/Pacific Islander     |           |                  | American Indian/Alaska Natived |                            |           | Hispanic <sup>e</sup>      |                   |                  |
|                            | Rateb     | APC°             |                                | Rateb                      | APC°      |                            | Rateb             | APC°             |
|                            | 2008-2012 | 2003-2012        |                                |                            | 2003-2012 |                            | 2008-2012         |                  |
| All Sites                  | 325.4     | -2.1*            | All Sites                      | 340.8                      | -1.8*     | All Sites                  | 395.0             | -1.9*            |
| Prostate                   | 74.0      | -4.8*            | Prostate                       | 67.1                       | -5.0*     | Prostate                   | 114.7             | -4.0*            |
| Lung and Bronchus          | 49.0      | -2.3*            | Lung and Bronchus              | 47.6                       | -3.7*     | Colon and Rectum           | 43.3              | -2.4*            |
| Colon and Rectum           | 42.2      | -2.2*            | Colon and Rectum               | 46.3                       | 0.0       | Lung and Bronchus          | 37.9              | -3.3*            |
| Liver & IBD <sup>f</sup>   | 20.9      | -1.2             | Kidney and Renal Pelvis        | 24.8                       | 1.0       | Non-Hodgkin Lymphoma       | 20.6              | 0.3              |
| Non-Hodgkin Lymphoma       | 16.6      | 0.1              | Liver & IBD <sup>f</sup>       | 19.9                       | 1.3       | Kidney and Renal Pelvis    | 20.2              | 0.6              |
| Urinary Bladder            | 15.8      | -1.6*            | Urinary Bladder                | 15.6                       | -1.0      | Urinary Bladder            | 19.6              | -1.5*            |
| Stomach                    | 14.5      | -3.9*            | Non-Hodgkin Lymphoma           | 14.6                       | 1.1       | Liver & IBD <sup>f</sup>   | 19.1              | 2.8*             |
| Kidney and Renal Pelvis    | 11.6      | 1.6              | Oral Cavity and Pharynx        | 13.2                       | 4.5       | Stomach                    | 14.2              | -2.4*            |
| Oral Cavity and Pharynx    | 11.0      | -0.1             | Stomach                        | 12.3                       | -4.1      | Leukemia                   | 12.6              | -0.3             |
| Pancreas                   | 10.8      | 0.4              | Pancreas                       | 11.1                       |           | Pancreas                   | 11.9              | 0.1              |
| Leukemia                   | 9.8       | 0.3              | Leukemia                       | 10.1                       | 2.8       | Oral Cavity and Pharynx    | 10.1              | 1.1              |
| Thyroid                    | 6.2       | 6.4*             | Esophagus                      | 4.9                        | _         | Myeloma                    | 7.3               | 0.7              |
| Myeloma                    | 4.6       | 0.9              | Testis                         | 4.8                        | _         | Brain and ONS <sup>f</sup> | 5.8               | -2.0*            |
| Brain and ONSf             | 4.3       | 0.3              | Myeloma                        | 4.6                        | _         | Esophagus                  | 5.2               | -1.2             |
| Esophagus                  | 3.6       | -2.8             | Larynx                         | 4.3                        | _         | Testis                     | 4.9               | 2.8*             |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,
Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia
excluding ATL/RG).

- a Top 15 cancer sites selected based on 2008-2012 age-adjusted rates for the race/ethnic group.
- Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.26

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity

Females

White

Black

| AII NU  | .005   |  | WIII C   | , _   |   | Diac   |   |  |
|---|--|--|--|---|---|--|---|--|
|   | Rateb  | APC <sup>c</sup>   |  | Rateb   | APC°  |  | Rateb   | APC <sup>c</sup>   |
| -77 -61   | 2008-2012  |  | -22 04   | 2008-2012   |   | -11 -01.   | 2008-2012   |  |
| All Sites   | 411.2  | -0.1   | All Sites  | 423.9   | -0.1  | All Sites  | 401.2   | -0.2   |
| Breast  | 124.8  | 0.1  | Breast   | 127.9   | 0.0   | Breast   | 124.4   | 0.7*   |
| Lung and Bronchus   | 50.2   | -1.2*  | Lung and Bronchus  | 52.7  | -1.2*   | Lung and Bronchus  | 50.8  | -1.3*  |
| Colon and Rectum  | 37.1   | -2.6*  | Colon and Rectum   | 36.3  | -2.6*   | Colon and Rectum   | 46.0  | -2.8*  |
| Corpus and Uterus, NOS  | 25.1   | 1.6*   | Corpus and Uterus, NOS   | 25.8  | 1.4*  | Corpus and Uterus, NOS   | 24.0  | 2.9*   |
| Thyroid   | 20.0   | 5.5*   | Thyroid  | 21.3  | 5.5*  | Pancreas   | 14.4  | -0.3   |
| Melanoma of the Skin  | 16.8   | 0.7  | Melanoma of the Skin   | 20.2  | 0.8   | Kidney and Renal Pelvis  | 12.8  | 2.8*   |
| Non-Hodgkin Lymphoma  | 16.3   | -0.5*  | Non-Hodgkin Lymphoma   | 17.1  | -0.5*   | Non-Hodgkin Lymphoma   | 12.1  | -0.1   |
| Ovary <sup>g</sup>  | 12.1   | -1.6*  | Ovary <sup>g</sup>   | 12.8  | -1.6*   | Thyroid  | 11.8  | 5.3*   |
| Pancreas  | 11.0   | 0.6*   | Kidney and Renal Pelvis  |   | 1.3*  | Myeloma  | 11.2  | 1.1  |
| Kidney and Renal Pelvis   |  | 1.3*   | Leukemia   | 10.9  | 0.3   | Ovary <sup>g</sup>   | 9.8   | -1.4*  |
| Leukemia  | 10.4   | 0.3  | Pancreas   | 10.8  | 0.7*  | Cervix Uteri   | 9.2   | -3.1*  |
| Urinary Bladder   | 8.7  | -1.3*  | Urinary Bladder  | 9.4   | -1.2*   | Leukemia   | 8.5   | 0.1  |
| Cervix Uteri  | 7.7  | -1.5*  | Cervix Uteri   | 7.7   | -1.0*   | Stomach  | 8.4   | -0.9   |
| Oral Cavity and Pharynx   |  | 0.2  | Oral Cavity and Pharynx  |   | 0.6*  | Urinary Bladder  | 6.9   | -1.5   |
| Brain and ONS <sup>f</sup>  | 5.4  | -0.8*  | Brain and ONS <sup>f</sup>   | 5.9   | -0.7*   | Oral Cavity and Pharynx  | 5.2   | -2.3*  |
| Asian/Pacific Islander  |  |  | American Indian/Alaska Native <sup>d</sup>   |   |   | Hispanic <sup>e</sup>  |   |  |
|   | Rate <sup>b</sup><br>2008-2012   | APC <sup>c</sup><br>2003-2012  |  | Rate <sup>b</sup><br>2008-2012  | APC <sup>c</sup><br>2003-2012   |  | Rate <sup>b</sup><br>2008-2012  | APC <sup>c</sup><br>2003-2012  |
| All Sites   |  |  |  | 2000 2012   |   |  |   |  |
| Breast  | 297 5  |  | All Sites  | 308 8   |   | All Sites  |   | -0.2   |
|   | 297.5<br>96.3  | 0.1  | All Sites<br>Breast  | 308.8   | -0.8  | All Sites<br>Breast  | 322.2   | -0.2   |
|   | 96.3   | 0.1<br>0.9*  | Breast   | 82.0  | -0.8<br>0.0   | Breast   | 322.2<br>92.1   | 0.2  |
| Colon and Rectum  | 96.3<br>31.3   | 0.1<br>0.9*<br>-2.2*   | Breast<br>Colon and Rectum   | 82.0<br>35.7  | -0.8<br>0.0<br>-3.1*  | Breast<br>Colon and Rectum   | 322.2<br>92.1<br>30.0   | 0.2<br>-2.0*   |
| Colon and Rectum<br>Lung and Bronchus   | 96.3<br>31.3<br>28.5   | 0.1<br>0.9*<br>-2.2*<br>-0.3   | Breast<br>Colon and Rectum<br>Lung and Bronchus  | 82.0<br>35.7<br>34.5  | -0.8<br>0.0<br>-3.1*<br>-4.1*   | Breast<br>Colon and Rectum<br>Lung and Bronchus  | 322.2<br>92.1<br>30.0<br>25.1   | 0.2<br>-2.0*<br>-1.3*  |
| Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS   | 96.3<br>31.3<br>28.5<br>19.9   | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*   | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS  | 82.0<br>35.7<br>34.5<br>19.8  | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1  | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7   | 0.2<br>-2.0*<br>-1.3*<br>2.4*  |
| Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS<br>Thyroid  | 96.3<br>31.3<br>28.5<br>19.9<br>19.3   | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*   | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS<br>Kidney and Renal Pelvis   | 82.0<br>35.7<br>34.5<br>19.8<br>13.9  | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9  | Breast<br>Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS<br>Thyroid   | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1   | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*  |
| Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS<br>Thyroid<br>Non-Hodgkin Lymphoma  | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3   | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4   | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid   | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9  | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*  | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5   | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3  |
| Colon and Rectum<br>Lung and Bronchus<br>Corpus and Uterus, NOS<br>Thyroid<br>Non-Hodgkin Lymphoma<br>Ovary <sup>s</sup>  | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4                                    | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*  | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma  | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1  | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2  | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6   | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*  |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>9</sup> Pancreas  | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3                             | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*  | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary  | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0                                    | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1                                      | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6   | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1  |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>9</sup> Pancreas Stomach  | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8                      | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*                                 | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>9</sup> Pancreas  | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9                             | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6                              | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>g</sup> Pancreas  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0                                     | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2                                  |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>9</sup> Pancreas Stomach Liver & IBD <sup>f</sup>   | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8<br>7.9               | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*<br>-1.4                         | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>9</sup> Pancreas Liver & IBD <sup>f</sup>                               | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9<br>8.4                      | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6<br>2.2                       | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>9</sup> Pancreas Cervix Uteri   | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0<br>10.3<br>9.9                      | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2<br>-4.4*                         |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>S</sup> Pancreas Stomach Liver & IBD <sup>f</sup> Leukemia                                      | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8<br>7.9<br>6.3        | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*<br>-1.4<br>-0.4                 | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>3</sup> Pancreas Liver & IBD <sup>f</sup> Stomach                       | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9<br>8.4<br>7.5               | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6<br>2.2<br>1.5                | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>9</sup> Pancreas Cervix Uteri Leukemia                                  | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0<br>10.3<br>9.9<br>8.9               | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2<br>-4.4*<br>0.4                  |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>S</sup> Pancreas Stomach Liver & IBD <sup>f</sup> Leukemia Cervix Uteri                         | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8<br>7.9<br>6.3<br>6.3 | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*<br>-1.4<br>-0.4<br>-3.2*        | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>g</sup> Pancreas Liver & IBD <sup>f</sup> Stomach Cervix Uteri          | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9<br>8.4<br>7.5<br>7.5        | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6<br>2.2<br>1.5<br>-1.2        | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>9</sup> Pancreas Cervix Uteri Leukemia Stomach                          | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0<br>10.3<br>9.9<br>8.9<br>8.4        | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2<br>-4.4*<br>0.4<br>-1.8*         |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>3</sup> Pancreas Stomach Liver & IBD <sup>f</sup> Leukemia Cervix Uteri Kidney and Renal Pelvis | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8<br>7.9<br>6.3<br>6.3 | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*<br>-1.4<br>-0.4<br>-3.2*<br>0.8 | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>g</sup> Pancreas Liver & IBD <sup>f</sup> Stomach Cervix Uteri Leukemia | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9<br>8.4<br>7.5<br>7.5<br>7.2 | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6<br>2.2<br>1.5<br>-1.2<br>0.6 | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>g</sup> Pancreas Cervix Uteri Leukemia Stomach Liver & IBD <sup>f</sup> | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0<br>10.3<br>9.9<br>8.9<br>8.4<br>7.0 | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2<br>-4.4*<br>0.4<br>-1.8*<br>2.4* |
| Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Ovary <sup>S</sup> Pancreas Stomach Liver & IBD <sup>f</sup> Leukemia Cervix Uteri                         | 96.3<br>31.3<br>28.5<br>19.9<br>19.3<br>11.3<br>9.4<br>9.3<br>8.8<br>7.9<br>6.3<br>6.3 | 0.1<br>0.9*<br>-2.2*<br>-0.3<br>2.6*<br>4.9*<br>-0.4<br>-1.2*<br>1.5*<br>-3.3*<br>-1.4<br>-0.4<br>-3.2*        | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Kidney and Renal Pelvis Thyroid Non-Hodgkin Lymphoma Ovary <sup>g</sup> Pancreas Liver & IBD <sup>f</sup> Stomach Cervix Uteri          | 82.0<br>35.7<br>34.5<br>19.8<br>13.9<br>12.9<br>11.1<br>10.0<br>8.9<br>8.4<br>7.5<br>7.5<br>7.2 | -0.8<br>0.0<br>-3.1*<br>-4.1*<br>2.1<br>-1.9<br>6.9*<br>-1.2<br>-2.1<br>-2.6<br>2.2<br>1.5<br>-1.2        | Breast Colon and Rectum Lung and Bronchus Corpus and Uterus, NOS Thyroid Non-Hodgkin Lymphoma Kidney and Renal Pelvis Ovary <sup>9</sup> Pancreas Cervix Uteri Leukemia Stomach                          | 322.2<br>92.1<br>30.0<br>25.1<br>20.7<br>18.1<br>15.5<br>11.6<br>11.0<br>10.3<br>9.9<br>8.9<br>8.4        | 0.2<br>-2.0*<br>-1.3*<br>2.4*<br>5.5*<br>-0.3<br>2.0*<br>-1.1<br>-0.2<br>-4.4*<br>0.4<br>-1.8*         |

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).


- <sup>a</sup> Top 15 cancer sites selected based on 2008-2012 age-adjusted rates for the race/ethnic group.
- Bates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- The APC is the Annual Percent Change over the time interval.
- Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups Census P25-1130).
- d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
- Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
- IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
- Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
- \* The APC is significantly different from zero (p<.05).

All Races

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

## Figure 1.13

## SEER Incidence 2003-2012 Males by Race/Ethnicity



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).


Regression lines are calculated using the Joinpoint Regression Program Version 4.2.0, April 2015, National Cancer Institute.

a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

## Figure 1.14

## SEER Incidence 2003-2012 Females by Race/Ethnicity



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.2.0, April 2015, National Cancer Institute.

<sup>&</sup>lt;sup>a</sup> Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.